Navigation Links
Arthrosurface's Revolutionary Toe Implant Hits 9 Year Mark
Date:1/7/2014

e disease begins. Ironically, all of the toe implants that existed prior to the HemiCAP® actually resurfaced the least problematic side of the joint. Since the launch of our toe implant, several competitors have followed with their metatarsal based implants; however, no other predicate devices with a threaded cementless fixation option currently exist. Remarkably, some predicate devices simply rely on a stem pressed into the shaft of the metatarsal. We relied on our outstanding peer reviewed published clinical data to obtain this cementless clearance," commented Steve Ek, CEO of Arthrosurface, Inc.

Dr. Carl Hasselman, Foot and Ankle Specialist at UPMC in Pittsburgh noted; "I realized over 10 years ago that toe fusion should not be the gold standard for first ray arthritis because it did not preserve motion. Supported by published results and the 300+ HemiCAPs® which I have personally implanted, I have never seen a component loosen in my 9 years of experience. Patients fly in from all over the country to receive the HemiCAP® and I have even taken well fused toe joints apart because the patients were having pain from the stiffness of their joint. Other physicians are slowly but surely realizing that the HemiCAP® is a very viable alternative for the treatment of hallux rigidus and I am convinced that the outcomes and the strong screw fixation will stand the test of time."

About Arthrosurface

Arthrosurface, Inc. is a leader in the design and distribution of orthopedic devices for joint preservation, restoration and resurfacing. The Company's HemiCAP® system is a unique, less invasive technology that can be used to treat a wide variety of joint conditions caused by trauma, injury and disease. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world
'/>"/>

SOURCE Arthrosurface Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Airway Company Launches Revolutionary New Speaking Valve And Heat Moisture Exchanger
2. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
3. Aging to Be Reversed through Revolutionary New Category of Diagnostics
4. Femasys Launches FemCerv Endocervical Sampler, A Revolutionary Solution For Cervical Cancer Screening
5. Third FDA Clearance for Revolutionary Simbionix Product
6. A Revolutionary Treatment for Burns & Bone Fractures
7. Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
8. Kimberly-Clark Introduces Revolutionary CERVICOOL Cooled Radiofrequency System for Cervical Joint Pain
9. Kimberly-Clark Introduces Revolutionary CERVICOOL Cooled Radiofrequencey System for Cervical Joint Pain
10. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
11. Award Winning Inventor Creates Revolutionary Gadget For Healthy Bowel Movements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DIEGO , July 24, 2014 ... industry leader in bioactive lipid-targeted therapeutics, reported interim ... where ASONEP™ is being investigated as a treatment ... that have failed at least one therapy involving ... no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), ...
(Date:7/24/2014)... N.J., July 24, 2014 , Revenues ... year , Adjusted diluted EPS from continuing operations of ... EPS from continuing operations of $0.92, 7% below prior year ... versus prior year , Full year 2014 revenues now ... to 4% previously , Full year 2014 adjusted diluted ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... increases your risk of death, but recessions decrease ... While previous studies of individuals have shown that ... mortality rate, more comprehensive studies have shown, unexpectedly, ... increase. Researchers from Drexel University and the University ... better understand these seemingly contradictory findings. , Using ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
(Date:7/24/2014)... known as neonicotinoids, were found commonly in streams ... study. This is the first broad-scale investigation of ... one of the first conducted within the United ... of insect pests, use of neonicotinoid insecticides has ... United States, particularly in the Midwest. The ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Joblessness could kill you, but recessions could be good for your health 2Health News:Joblessness could kill you, but recessions could be good for your health 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... aid in understanding ADD and more , FRIDAY, Aug. 28 ... a crowd, it appears that your "mind,s eye" acts like ... until you find the right person. , Researchers from the ... as they searched for a specific tilted, colored bar among ...
... 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,the Beijing Public Health Bureau has selected ... Sinovac,s seasonal influenza vaccine, for,the benefit of the citizens ... process for the purchase of flu vaccines and,corresponding services ...
... , HARBIN, China, Aug. 28 ... Medical" or "the Company") (Nasdaq: CSKI ), ... People,s Republic of China ("PRC"), today announced that the,Company,s ... Thursday,September 24, 2009 at Harbin Shen Te Hotel which ...
... ... , ... (PRWEB) August 28, 2009 -- Promising cancer research treatment breakthrough seeks funding for corroboration., ... CHAI Foundation , a small 501(c)(3) non-profit medical research organization seeking to find ...
... , TOKYO, Aug. 28 ALOKA CO., ... generation of compact color ultrasound systems. This new multi-purpose system, ... fully upgradable and easy to use. , , ... ProSound Alpha 10 and Alpha 7, the ProSound Alpha 6 ...
... , TOSU, Saga, Japan and MIAMI, Aug. ... Inc. today announced the completion of their acquisition of Noven Pharmaceuticals, ... Inc., a wholly owned subsidiary of Hisamitsu U.S., Inc., with and ... the Agreement and Plan of Merger among the companies, at the ...
Cached Medicine News:Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 2Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 3Health News:Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 3Health News:Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: